SAR studies of non-zinc-chelating MMP-13 inhibitors: Improving selectivity and metabolic stability

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 17, 2010, Pages 5039-5043

  Gao, Donghong Amy ^a   Xiong, Zhaoming ^a   Heim Riether, Alexander ^a   Amodeo, Laura ^a   August, E Michael ^a   Cao, Xianhua ^a   Ciccarelli, Leonard ^a   Collins, Brandon K ^a   Harrington, Kyle ^a   Haverty, Kathleen ^a   Hill Drzewi, Melissa ^a   Li, Xiang ^a   Liang, Shuang ^a   Margarit, Steluta Mariana ^a   Moss, Neil ^a   Nagaraja, Nelamangala ^a   Proudfoot, John ^a   Roman, Rene ^a   Schlyer, Sabine ^a   Keenan, Lana Smith ^a   Taylor, Steven ^a   Wellenzohn, Bernd ^b   Wiedenmayer, Dieter ^b   Li, Jun ^a   Farrow, Neil A ^a   more..

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Metabolic stability; MMP 13; Non Zn chelating inhibitor; SAR; Selectivity

Indexed keywords

COLLAGENASE 3; COLLAGENASE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; DRUG CLEARANCE; DRUG STABILITY; DRUG SYNTHESIS; IN VIVO STUDY; LIPOPHILICITY; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

CHELATING AGENTS; MATRIX METALLOPROTEINASE 13; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; ZINC;

EID: 77955661111     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.07.036     Document Type: Article

References (45)

1. B. Fingleton Semin. Cell Dev. Biol. 19 2008 61
2. J. Huxley-Jones, S.M. Foord, and M.R. Barnes Drug Discovery Today 13 2008 685
3. A. Page-McCaw, A.J. Ewald, and Z. Werb Nat. Rev. Mol. Cell Biol. 8 2007 221
4. T.E. Cawston, and A.J. Wilson Best Pract. Res., Clin. Rheumatol. 20 2006 983
5. W.C. Parks, C.L. Wilson, and Y.S. López-Boado Nat. Rev. Immunol. 4 2004 617
6. H. Matter, and M. Schudok Curr. Opin. Drug Discov. Devel. 7 2004 513
7. J.F. Woessner, H. Nagase, Matrix Metalloproteinases and TIMPs 2000 Oxford University Press New York
8. D. Wernicke, C. Seyfert, B. Hinzmann, and I.E. Gromnica J. Rheumatol. 23 1996 590
9. V. Knäuper, H. Will, C. López-Otín, B. Smith, S.J. Atkinson, H. Stanton, R.M. Hembry, and G. Murphy J. Biol. Chem. 271 1996 17124
10. For recent reviews and references cited therein: H. Takaishi, T. Kimura, S. Dalal, Y. Okada, and J. D'Armiento Curr. Pharm. Biotechnol. 9 2008 47
11. A.D. Rowan, G.J. Litherland, W. Hui, and J.M. Milner Expert Opin. Ther. Targets 12 2008 1
12. G. Tardif, P. Reboul, J.P. Pelletier, and J. Martel-Pelletier Mod. Rheumatol. 14 2004 197
13. A.H. Drummond, P. Beckett, P.D. Brown, E.A. Bone, A.H. Davidson, and W.A. Galloway Ann. N.Y. Acad. Sci. 878 1999 228
14. J.W. Hutchinson, G.M. Tierney, S.L. Parsons, and T.R.C. Davies J. Bone Joint Surg. Br. 80 1998 907
15. S. Wojtowicz-Praga, J. Torri, M. Johnson, V. Steen, J. Marshall, E. Ness, R. Dickson, M. Sale, H.S. Rasmussen, T.A. Chiodo, and M.J. Hawkins J. Clin. Oncol. 16 1998 2150
16. A.W. Griffioen IDrugs 3 2000 336
17. N.C. Levitt, F.A.L.M. Eskens, K.J. O'Byrne, D.J. Propper, L.J. Denis, S.J. Owen, L. Choi, J.A. Foekens, S. Wilner, J.M. Wood, M. Nakajima, D.C. Talbot, W.P. Steward, A.L. Harris, and J. Verweij Clin. Cancer Res. 7 2001 1912
18. J.W. Skiles, N.C. Gonnella, and A.Y. Jeng Curr. Med. Chem. 8 2001 425
19. I.M. Clark, and A.E. Parker Expert Opin. Ther. Targets 7 2003 19
20. J.T. Peterson Heart Fail. Rev. 9 2004 63
21. D. Stickens, D.J. Behonick, N. Ortega, B. Heyer, B. Hartenstein, Y. Yu, A.J. Fosang, M. Schorpp-Kistner, P. Angel, and Z. Werb Development 131 2004 5883
22. M. Inada, Y. Wang, M.H. Byrne, M.U. Rahman, C. Miyaura, C. López-Otín, and S.M. Krane Proc. Natl. Acad. Sci. U.S.A. 101 2004 17192
23. A.M. Kennedy, M. Inada, S.M. Krane, P.T. Christie, B. Harding, C. López-Otín, L.M. Sánchez, A.J. Pannett, A. Dearlove, C. Hartley, M.H. Byrne, A. Reed, M.A. Nesbit, M.P. Whyte, and R.V. Thakker J. Clin. Invest. 115 2005 2832
24. A.R. Johnson, A.G. Pavlovsky, D.F. Ortwine, F. Prior, C.F. Man, D.A. Bornemeier, C.A. Banotai, W.T. Mueller, P. McConnell, C. Yan, V. Baragi, C. Lesch, W.H. Roark, M. Wilson, K. Datta, R. Guzman, H.K. Han, and R.D. Dyer J. Biol. Chem. 282 2007 27781
25. V.M. Baragi, G. Becher, A.M. Bendele, R. Biesinger, H. Bluhm, J. Boer, H. Deng, R. Dodd, M. Essers, T. Feuerstein, B.M. Gallagher, C. Gege, M. Hochgürtel, M. Hofmann, A. Jaworski, L. Jin, A. Kiely, B. Korniski, H. Kroth, D. Nix, B. Nolte, D. Piecha, T.S. Powers, F. Richter, M. Schneider, C. Steeneck, I. Sucholeiki, A. Taveras, A. Timmermann, J.V. Veldhuizen, J. Weik, X. Wu, and B. Xia Arthritis Rheum. 60 2009 2008
26. L.A. Reiter, K.D. Freeman-Cook, C.S. Jones, G.J. Martinelli, A.S. Antipas, M.A. Berliner, K. Datta, J.T. Downs, J.D. Eskra, M.D. Forman, E.M. Greer, R. Guzman, J.R. Hardink, F. Janat, N.F. Keene, E.R. Laird, J.L. Liras, L.L. Lopresti-Morrow, P.G. Mitchell, J. Pandit, D. Robertson, D. Sperger, M.L. Vaughn-Bowser, D.M. Waller, and S.A. Yocum Bioorg. Med. Chem. Lett. 16 2006 5822
27. It was initially believed that inhibition of MMP-1 or MMP-14 was the cause of MSS. Studies on MMP-14 KO mice support MMP-14 being a strong candidate for MSS: see Ref. 4b. However, clinical data with CP-544439, a non-selective hydroxamic acid-based MMP-13 inhibitor showed MSS side effects even though it is inactive against MMP-1. See: Reiter, L. A.; Robinson, R. P.; McClure, K. F.; Jones, C. S.; Reese, M. R.; Mitchell, P. G.; Otterness, I. G.; Bliven, M. L.; Liras, J.; Cortina, S. R.; Donahue, K. M.; Eskra, J. D.; Griffiths, R. J.; Lame, M. E.; Lopez-Anaya, A.; Martinelli, G. J.; McGahee, S. M.; Yocum, S. A.; Lopresti-Morrow, L. L.; Tobiassen, L. M.; Vaughn-Bowser, M. L. Bioorg. Med. Chem. Lett. 2004, 14, 3389.
28. For recent reviews on MMP inhibitors, see: E. Nuti, T. Tuccinardi, and A. Rossello Curr. Pharm. Des. 13 2007 2087
29. J. Hu, P.E. Van den Steen, Q.X. Sang, and G. Opdenakker Nat. Rev. Drug Disc. 6 2007 480
30. B.G. Rao Curr. Pharm. Des. 11 2005 295
31. E. Breuer, J. Frant, and R. Reich Expert Opin. Ther. Patents 15 2005 253
32. J.I. Levin Curr. Top. Med. Chem. 4 2004 1289
33. J.S. Skotnicki, M.J. DiGrandi, and J.I. Levin Curr. Opin. Drug Discov. Devel. 6 2003 742
34. For recent examples of reported selective MMP-13 inhibitors with Zn-binding groups, see: L.G. Monovich, R.A. Tommasi, R.A. Fujimoto, V. Blancuzzi, K. Clark, W.D. Cornell, R. Doti, J. Doughty, J. Fang, D. Farley, J. Fitt, V. Ganu, R. Goldberg, R. Goldstein, S. Lavoie, R. Kulathila, W. Macchia, D.T. Parker, R. Melton, E. O'Byrne, G. Pastor, T. Pellas, E. Quadros, N. Reel, D.M. Roland, Y. Sakane, H. Singh, J. Skiles, J. Somers, K. Toscano, A. Wigg, S. Zhou, L. Zhu, W.C. Shieh, S. Xue, and L.W. McQuire J. Med. Chem. 52 2009 3523
35. W. Li, Y. Hu, J. Li, J.R. Thomason, D. DeVincentis, X. Du, J. Wu, R. Hotchandani, T.S. Rush III, J.S. Skotnicki, S. Tam, P.S. Chockalingam, E.A. Morris, and J.I. Levin Bioorg. Med. Chem. Lett. 19 2009 4546
36. E. Nuti, F. Casalini, S.I. Avramova, S. Santamaria, G. Cercignani, L. Marinelli, V. La Pietra, E. Novellino, E. Orlandini, S. Nencetti, T. Tuccinardi, A. Martinelli, N.H. Lim, R. Visse, H. Nagase, and A. Rossello J. Med. Chem. 52 2009 4757
37. For reported examples of non-zinc binding and selective MMP-13 inhibitors, see: C.K. Engel, B. Pirard, S. Schimanski, R. Kirsch, J. Habermann, O. Klingler, V. Schlotte, K.U. Weithmann, and K.U. Wendt Chem. Biol. 12 2005 181
38. J.J. Li, J. Nahra, A.R. Johnson, A. Bunker, P. O'Brien, W.-S. Yue, D.F. Ortwine, C.-F. Man, V. Baragi, K. Kilgore, R.D. Dyer, and H.-K. Han J. Med. Chem. 51 2008 835
39. M.E. Schnute, P.M. O'Brien, J. Nahra, M. Morris, W.H. Roark, C.E. Hanau, P.G. Ruminski, J.A. Scholten, T.R. Fletcher, B.C. Hamper, J.N. Carroll, W.C. Patt, H.S. Shieh, B. Collins, A.G. Pavlovsky, K.E. Palmquist, K.W. Aston, J. Hitchcock, M.D. Rogers, J. McDonald, A.R. Johnson, G.E. Munie, A.J. Wittwer, C.-F. Man, S.L. Settle, O. Nemirovskiy, L.E. Vickery, A. Agawal, R.D. Dyer, and T. Sunyer Bioorg. Med. Chem. Lett. 20 2010 576
40. Another class of specific MMP-13 inhibitors were reported without structure, see Ref. 5e.
41. A. Heim-Riether, S.J. Taylor, S. Liang, D.A. Gao, Z. Xiong, E.M. August, B.K. Collins, B.T. Farmer II, K. Haverty, M. Hill-Drzewi, H.-D. Junker, S.M. Margarit, N. Moss, T. Neumann, J.R. Proudfoot, L. Smith-Keenan, R. Sekul, Q. Zhang, J. Li, and N.A. Farrow Bioorg. Med. Chem. Lett. 19 2009 5321
42. Goldberg, D. et al., results to be published.
43. A.S. Guram, A.O. King, J.G. Allen, X. Wang, L.B. Schenkel, J. Chan, E.E. Bunel, M.M. Faul, R.D. Larsen, M.J. Martinelli, and P.J. Reider Org. Lett. 8 2006 1787
44. 50s are greater than the top concentration (20 μM). For detailed assay conditions, see Ref. 10.
45. For comparison, compound 27 was also selected for an intravenous pharmacokinectics study. But the study failed due to its poor solubility (0.1 μg/mL).